These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 15506654)

  • 1. Effects of China-made recombinant human growth hormone on the treatment of growth hormone deficiency.
    Jiang J; Wang W; Sun WX; Wang XM; Ni JH; Chen FS; Wang DF
    Chin Med Sci J; 2004 Sep; 19(3):225-9. PubMed ID: 15506654
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Efficacy and safety of recombinant human growth hormone solution in children with growth hormone deficiency in China: a multicenter trial].
    Hou L; Luo XP; Du ML; Ma HM; Gong CX; Li YC; Shen SX; Zhao ZH; Liang L; Dong GP; Yan CY; Du HW
    Zhonghua Er Ke Za Zhi; 2009 Jan; 47(1):48-52. PubMed ID: 19573383
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic value of serum insulin-like growth factor binding protein-3 in children with or without growth hormone deficiency.
    Qin S; Shi Y; Deng J
    Chin Med Sci J; 2002 Sep; 17(3):160-3. PubMed ID: 12901539
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IGF-I and IGF binding protein-3 levels during initial GH dosage step-up are indicators of GH sensitivity in GH-deficient children and short children born small for gestational age.
    Ranke MB; Traunecker R; Martin DD; Schweizer R; Schwarze CP; Wollmann HA; Binder G
    Horm Res; 2005; 64(2):68-76. PubMed ID: 16113581
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relevance of IGF-I, IGFBP-3, and IGFBP-2 measurements during GH treatment of GH-deficient and non-GH-deficient children and adolescents.
    Ranke MB; Schweizer R; Elmlinger MW; Weber K; Binder G; Schwarze CP; Wollmann HA
    Horm Res; 2001; 55(3):115-24. PubMed ID: 11549872
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of a biosimilar recombinant human growth hormone (r-hGH Cristalia) compared with reference r-hGH in children with growth hormone deficiency (CERES study): A randomized, multicentric, investigator-blind, phase 3 trial.
    Czepielewski MA; Garret Q; Vencio SAC; Rassi N; Felicio JS; Faria MS; Senn CCP; Bronstein MD; Cerqueira MJAG; Neves ACL; Sgarbi JA; Spinola-Castro AM; Cunha MPR; Bandeira F; Toffoletto O; Afiune J; Baradelli R; Rodrigues DG; Scharf M
    Growth Horm IGF Res; 2019; 48-49():29-35. PubMed ID: 31493626
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dose-dependent effects of recombinant human growth hormone on biochemical markers of bone and collagen metabolism in adult growth hormone deficiency.
    Bollerslev J; Møller J; Thomas S; Djøseland O; Christiansen JS
    Eur J Endocrinol; 1996 Dec; 135(6):666-71. PubMed ID: 9025710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum free insulin-like growth factor I (IGF-I), total IGF-I, and IGF-binding protein-3 concentrations in normal children and children with growth hormone deficiency.
    Kawai N; Kanzaki S; Takano-Watou S; Tada C; Yamanaka Y; Miyata T; Oka M; Seino Y
    J Clin Endocrinol Metab; 1999 Jan; 84(1):82-9. PubMed ID: 9920066
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Urinary pyridinium collagen cross-links predict growth performance in children with idiopathic short stature and with growth hormone (GH) deficiency treated with GH. Skeletal metabolism during GH treatment.
    Spagnoli A; Branca F; Spadoni GL; Cianfarani S; Pasquino AM; Argirò G; Vitale S; Robins SP; Boscherini B
    J Clin Endocrinol Metab; 1996 Oct; 81(10):3589-93. PubMed ID: 8855806
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum leptin and IGF-I during growth hormone treatment in chronic renal failure.
    Patel L; Webb NJ; Bradbury MG; Zaman N; Smith P; Lewis MA; Postlethwaite RJ; Price DA; Clayton PE
    Pediatr Nephrol; 2002 Aug; 17(8):643-7. PubMed ID: 12185474
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Growth hormone (GH) provocative retesting of 108 young adults with childhood-onset GH deficiency and the diagnostic value of insulin-like growth factor I (IGF-I) and IGF-binding protein-3.
    Juul A; Kastrup KW; Pedersen SA; Skakkebaek NE
    J Clin Endocrinol Metab; 1997 Apr; 82(4):1195-201. PubMed ID: 9100596
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elevated insulin-like growth factor-I values in children with Prader-Willi syndrome compared with growth hormone (GH) deficiency children over two years of GH treatment.
    Feigerlová E; Diene G; Oliver I; Gennero I; Salles JP; Arnaud C; Tauber M
    J Clin Endocrinol Metab; 2010 Oct; 95(10):4600-8. PubMed ID: 20926543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effect of recombinant human growth hormone on glucose metabolism in children with growth hormone deficiency].
    Liang L; Zou CC; Li Y; Wang CL; Jiang YJ; Dong GP; Fu JF; Wang XM
    Zhonghua Er Ke Za Zhi; 2006 Sep; 44(9):657-61. PubMed ID: 17217656
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum levels of insulin-like growth factor binding proteins (IGFBP)-4 and -5 correlate with bone mineral density in growth hormone (GH)-deficient adults and increase with GH replacement therapy.
    Thorén M; Hilding A; Brismar T; Magnusson P; Degerblad M; Larsson L; Sääf M; Baylink DJ; Mohan S
    J Bone Miner Res; 1998 May; 13(5):891-9. PubMed ID: 9610754
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum IGF-I and IGFBP-3 concentrations do not accurately predict growth hormone deficiency in children with brain tumours.
    Weinzimer SA; Homan SA; Ferry RJ; Moshang T
    Clin Endocrinol (Oxf); 1999 Sep; 51(3):339-45. PubMed ID: 10469014
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A low starting dose of genotropin in growth hormone-deficient adults.
    Janssen YJ; Frölich M; Roelfsema F
    J Clin Endocrinol Metab; 1997 Jan; 82(1):129-35. PubMed ID: 8989246
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The -202 A allele of insulin-like growth factor binding protein-3 (IGFBP3) promoter polymorphism is associated with higher IGFBP-3 serum levels and better growth response to growth hormone treatment in patients with severe growth hormone deficiency.
    Costalonga EF; Antonini SR; Guerra-Junior G; Mendonca BB; Arnhold IJ; Jorge AA
    J Clin Endocrinol Metab; 2009 Feb; 94(2):588-95. PubMed ID: 18984657
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of a low molecular mass form of insulin-like growth factor binding protein-3 (17.7 kilodaltons) in urine and serum from healthy children and growth hormone (GH)-deficient patients: relationship with GH therapy.
    Spagnoli A; Gargosky SE; Spadoni GL; MacGillivray M; Oh Y; Boscherini B; Rosenfeld RG
    J Clin Endocrinol Metab; 1995 Dec; 80(12):3668-76. PubMed ID: 8530618
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The correlation of the IGF-I, IGFBP-3, and ALS generation test to height velocity after 6 months of recombinant growth hormone therapy in girls with Turner syndrome.
    Collett-Solberg PF; Pessoa de Queiroz AN; Cardoso ME; Jusan RC; Vaisman M; Guimarães MM
    Growth Horm IGF Res; 2006 Aug; 16(4):240-6. PubMed ID: 16908209
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in serum insulin-like growth factor I (IGF-I) and IGF-binding protein-3 levels during growth hormone treatment in prepubertal short children born small for gestational age.
    Boguszewski M; Jansson C; Rosberg S; Albertsson-Wikland K
    J Clin Endocrinol Metab; 1996 Nov; 81(11):3902-8. PubMed ID: 8923836
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.